Clinical Trial Update: IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection

View source ↗

Summary

A clinical trial update describing primary-data collection on treatment experience for IgA nephropathy patients treated with iptacopan and/or atrasentan.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Atrasentan (atrasentan)
• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: IgA Nephropathy | Status: NOT_YET_RECRUITING